by Genova Marketing Department

On October 14, the "Opportunities and challenges for the development of China's biomedical industry and the SAPA 2021 China Annual Meeting of the American Association for the development of traditional Chinese medicine", sponsored by the Sino American pharmaceutical professionals association – China (SAPA China) and co organized by the Management Committee of Suzhou high tech Zone, was grandly held in Suzhou high tech Zone. More than 1500 scholars from the world's top scientific research institutions and leaders of large multinational pharmaceutical and biotechnology innovation enterprises attended the conference. Focusing on the ecosystem of China's pharmaceutical and biotechnology development, strategies to promote pharmaceutical innovation and the most cutting-edge science and technology, the conference held a series of activities such as high-level forum, special forum, project docking, financing promotion and enterprise exhibition.

At the vaccine development forum, Dr. Shen Chun, CEO of Genova, made an important report on the topic of the "International strategy for the development of the New Coronavirus（Covid-19） pDNA vaccine". Its detailed analysis of the current global COVID-19 situation and the large-scale preparation of DNA vaccine have received a strong response from the participants. At present, although the domestic epidemic has been effectively controlled , the virus mutates frequently abroad, and the crisis is still delayed and repeated all over the world. According to the statistics of the World Health Organization, nearly 2.5 billion people in 130 countries have not been vaccinated. The global gap in the number of New Coronavirus（Covid-19） vaccines is gradually expanding. The World Health Organization believes that insufficient and uneven vaccine supply remains the greatest threat to ending the worst phase of the pandemic and promoting global recovery. As long as the virus continues to spread everywhere, trade and travel will continue to be disturbed, economic recovery will be further hindered, and continued transmission also means that more variants of the vaccine may be avoided.

CDMO is a kind of drug R & D and production outsourcing service, which is widely used in the production of small molecule drugs and biological drugs. However, before that, the production mode of CDMO had not been started in China's vaccine field. The CDMO model of vaccine, first of all, is vaccine R & D and vaccine design and early R & D by enterprises. They can conduct their own production and entrust CDMO enterprises to carry out clinical production in the pre clinical and clinical production stages, and then the person in charge of vaccine marketing Licensor shall apply for vaccine registration. In the vaccine production after registration and approval, the marketing Licensor can entrust part or all of the production capacity to the vaccine CDMO enterprise.

Through the CDMO service of New Coronavirus（Covid-19) vaccine provided by Genova Biotech for international partners, it can quickly improve the vaccine production capacity and expand the countries, regions and populations benefited by the New Coronavirus（Covid-19） vaccine, especially pDNA vaccine; It is conducive to improving the level of global vaccine production and quality management, improving the production capacity of vaccine varieties with seriously insufficient domestic and international supply, and benefiting more people at home and abroad; It is conducive to China's vaccine industry for China and the global epidemic prevention and control and various action plans for the elimination of infectious diseases, and helps China become a major contributor to the R & D and production of international public health products.